2. Search Result
Search Result
Results for "

femur

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-107863
    Fructooligosaccharides

    Oligolevulose

    		 Biochemical Assay Reagents Bacterial Infection Metabolic Disease
    Fructooligosaccharides (Oligolevulose) are a class of orally active dietary fibers and prebiotics. Fructooligosaccharides exist in foods such as breast milk, wheat, honey, onions, garlic and bananas. Fructooligosaccharides resist hydrolysis by the body's digestive enzymes and stimulate the growth of beneficial intestinal bacteria through colonic fermentation. Fructooligosaccharides significantly prevent bone loss in the femur and lumbar spine .
    Fructooligosaccharides
  • HY-131034
    LP-922056
    1 Publications Verification

    		 Wnt Others
    LP-922056 is an orally active, highly potent Notum Pectinacetylesterase inhibitor with EC50s of 21 nM, 55 nM in human and mouse cellular assay, respectively. LP-922056 significantly increases midshaft femur cortical bone thickness in mice and rats .
    LP-922056
  • HY-P3497A
    Fmoc-Cys-Asp10 TFA

    		Amino Acid Derivatives Others
    Fmoc-Cys-Asp10 (TFA) is a non-releasable oligopeptide linker, involves in the synthesis of releasable oligopeptide linker. Releasable oligopeptide linker can be used to deliver agent to a bone fracture-homing oligopeptide and reduces fractured femur healing times .
    Fmoc-Cys-Asp10 TFA
  • HY-176547
    FGFR2/3-IN-3

    		FGFR Cytochrome P450 Endocrinology
    FGFR2/3-IN-3 is a dual-target FGFR2/3 inhibitor with IC50s of 2.7 nM (TEL-FGFR2) and 3.9 nM (TEL-FGFR3), respectively. FGFR2/3-IN-3 has effective activity against both wild-type and mutant FGFR3. FGFR2/3-IN-3 has low CYP3A4 inhibitory effect and hERG toxicity. FGFR2/3-IN-3 improves the imbalance between chondrocyte proliferation and differentiation and promotes bone growth by inhibiting the signaling pathway mediated by mutant FGFR3. FGFR2/3-IN-3 shows a growth-promoting effect in a dwarfism mouse model and has the potential to study bone development disorder-related diseases such as achondroplasia (ACH) .
    FGFR2/3-IN-3
  • HY-P3497
    Fmoc-Cys-Asp10

    		Amino Acid Derivatives Others
    Fmoc-Cys-Asp10 is a non-releasable oligopeptide linker, involves in the synthesis of releasable oligopeptide linker. Releasable oligopeptide linker can be used to deliver agent to a bone fracture-homing oligopeptide and reduces fractured femur healing times .
    Fmoc-Cys-Asp10
  • HY-W746269
    KCA 098

    		Drug Derivative Metabolic Disease
    KCA 098 is an orally active benzofuroquinoline derivative. KCA 098 can inhibit bone resorption and stimulat bone formation of chick embryo. KCA 098 can increase calcium and phosphorus content as well as the amount of force required to break the femur from ovariectomized rats. KCA 098 can be used for the research of bone diseases .
    KCA 098
  • HY-138089
    17β-Hydroxy exemestane

    		Androgen Receptor Estrogen Receptor/ERR LDLR Metabolic Disease Cancer
    17β-Hydroxy exemestane (17-H-EXE) is the primary active metabolite of Exemestane (HY-13632). 17β-Hydroxy exemestane is an aromatase inhibitor (IC50 = 69 nM) and an androgen receptor (AR) agonist (IC50 = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC50 = 21.2 μM). 17β-Hydroxy exemestane stimulates growth of AR- and ERα-positive MCF-7 (EC50= 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7 cells. 17β-Hydroxy exemestane inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae in ovariectomized rats .
    17β-Hydroxy exemestane

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: